Amanote Research
Register
Sign In
The EZH2 Inhibitor Tazemetostat Is Well Tolerated in a Phase I Trial
Cancer Discovery
- United States
doi 10.1158/2159-8290.cd-rw2018-067
Full Text
Open PDF
Abstract
Available in
full text
Categories
Oncology
Date
April 20, 2018
Authors
Unknown
Publisher
American Association for Cancer Research (AACR)
Related search
Epacadostat Plus Pembrolizumab Is Well Tolerated in a Phase I Trial
Cancer Discovery
Oncology
Interim Update From a Phase 2 Multicenter Study of Tazemetostat, an Ezh2 Inhibitor, in Patients With Relapsed or Refractory Follicular Lymphoma
Hematological Oncology
Medicine
Cancer Research
Oncology
Hematology
Interim Report From a Phase 2 Multicenter Study of Tazemetostat, an Ezh2 Inhibitor, in Patients With Relapsed or Refractory B-Cell Non-Hodgkin Lymphomas
Hematological Oncology
Medicine
Cancer Research
Oncology
Hematology
Imepitoin Is Well Tolerated in Healthy and Epileptic Cats
BMC Veterinary Research
Medicine
Veterinary
P1.01-94 Phase I Trial to Establish Maximum Tolerated Dose Safety and Pharmacokinetic Profile of Oral Paclitaxel
Journal of Thoracic Oncology
Medicine
Oncology
Respiratory Medicine
Pulmonary
Subcutaneous Treprostinil Is Well Tolerated With Infrequent Site Changes and Analgesics
Pulmonary Circulation
Pulmonary
Respiratory Medicine
A Phase I Clinical Trial of FOLFIRI in Combination With the Pan-Cyclin-Dependent Kinase (CDK) Inhibitor Flavopiridol
Cancer Chemotherapy and Pharmacology
Cancer Research
Toxicology
Oncology
Pharmacology
A Phase I Trial of MK-0731, a Kinesin Spindle Protein (KSP) Inhibitor, in Patients With Solid Tumors
Investigational New Drugs
Oncology
Pharmacology
Phase I Clinical Trial to Determine the Feasibility and Maximum Tolerated Dose of Panitumumab to Standard Gemcitabine-Based Chemoradiation in Locally Advanced Pancreatic Cancer
Clinical Cancer Research
Cancer Research
Oncology
